Published in Nucl Med Biol on January 10, 2017
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
Cancer stem cells: models and concepts. Annu Rev Med (2007) 8.06
Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 6.38
Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer (2010) 1.85
Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study. J Nucl Med (2009) 1.69
Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm (2005) 1.48
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol (2010) 1.44
Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res (2004) 1.38
Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. Nucl Med Biol (2000) 1.32
Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res (2003) 1.31
Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. Nucl Med Biol (1999) 1.24
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol (2009) 1.23
Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol (2013) 1.23
Cancer stem cells: a new paradigm for understanding tumor progression and therapeutic resistance. Surgery (2007) 1.22
Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer. Gynecol Oncol (2014) 1.15
Molecular approaches to personalizing management of ovarian cancer. Ann Oncol (2011) 1.15
Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J Oncol (2011) 1.15
B7-h3 and its role in antitumor immunity. Clin Dev Immunol (2010) 1.14
Radiosensitizers in cervical cancer. Cisplatin and beyond. Radiat Oncol (2006) 1.07
Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res (2012) 1.06
Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother Radiopharm (2013) 1.05
213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model. Cancer Res (2008) 1.04
A 94,000-dalton glycoprotein expressed by human melanoma and carcinoma cells. J Natl Cancer Inst (1982) 1.02
Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35. J Nucl Med (2005) 1.00
Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer (2007) 0.95
Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res (2007) 0.93
The potential and hurdles of targeted alpha therapy - clinical trials and beyond. Front Oncol (2014) 0.90
Extracelluar matrix metalloproteinase as a novel target for pancreatic cancer therapy. Anticancer Drugs (2011) 0.89
Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab. J Nucl Med (2014) 0.89
Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance. Cancer Treat Rev (2012) 0.89
Intracavitary radioimmunotherapy to treat solid tumors. Cancer Biother Radiopharm (2008) 0.89
Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb. PLoS One (2013) 0.87
Is sphere assay useful for the identification of cancer initiating cells of the ovary? Int J Gynecol Cancer (2015) 0.86
Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells. Proc Natl Acad Sci U S A (2008) 0.85
Biokinetic Modeling and Dosimetry for Optimizing Intraperitoneal Radioimmunotherapy of Ovarian Cancer Microtumors. J Nucl Med (2016) 0.84
Evaluation of platinum chemotherapy in combination with HER2-targeted α-particle radiation. Cancer Biother Radiopharm (2013) 0.84
The site of IgG2a catabolism in the rat. Mol Immunol (1981) 0.84
Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974. Lab Invest (2015) 0.84
Methodology for labeling proteins and peptides with lead-212 (212Pb). Nucl Med Biol (2013) 0.83
Targeting ovarian cancer-initiating cells. Anticancer Agents Med Chem (2010) 0.82
Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. Gynecol Oncol (2013) 0.81
The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype. Cancer Res (2016) 0.80
Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease. MAbs (2015) 0.80
Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer. Oncotarget (2016) 0.79
Syngeneic anti-idiotypic antisera to murine anti-HLA class II monoclonal antibodies. J Immunol (1987) 0.78
Application of (212)Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation. AIMS Med Sci (2015) 0.78
Imaging, biodistribution, and toxicology evaluation of (212)Pb-TCMC-trastuzumab in nonhuman primates. Nucl Med Biol (2016) 0.76
Novel tumor antigen-specific monoclonal antibody-based immunotherapy to eradicate both differentiated cancer cells and cancer-initiating cells in solid tumors. Semin Oncol (2014) 0.76